Clinical Trial Update: Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety trial of TJCS for moderate to severe dry eye disease has completed; the document references the study but does not include results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• TJCS

Snippet

Sponsor: Taejoon Pharmaceutical Co., Ltd. | Conditions: Dry Eye Syndromes | Phase 3 | Status: COMPLETED